AZD7442 Pharmacokinetics, Pharmacodynamics, and safety evaluation in pediatrics - TRUST

Study identifier:D8850C00006

ClinicalTrials.gov identifier:NCT05281601

EudraCT identifier:2021-006056-13

CTIS identifier:N/A

Study Complete

Official Title

Open-Label, Uncontrolled, Single dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of AZD7442 in Pediatric Participants Aged ≥ 29 weeks Gestational Age to < 18 years

Medical condition

SARS-CoV-2

Phase

Phase 1

Healthy volunteers

No

Study drug

AZD7442

Sex

All

Actual Enrollment

46

Study type

Interventional

Age

0 Years - 17 Years

Date

Study Start Date: 21 Mar 2022
Primary Completion Date: 16 Apr 2024
Study Completion Date: 16 Apr 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 May 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria